Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial

• Published in: Therapeutic advances in medical oncology Vol. 11; p. 1758835919853971
• Main Authors: Crocamo, Susanne, Binato, Renata, de Paula, Bruno, Vignal, Giselle, Magalhães, Lídia, Sarmento, Roberta, Accioly, Maria Theresa, Small, Isabele, Gioia, Sandra, Maroun, Pedro, Moutinho, Pamela, Freitas, Vivianne, Catein, Karuline, Abdelhay, Eliana
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.05.2019; Sage Publications Ltd; SAGE Publishing
• Subjects: Antitumor agents; Breast cancer; Chemotherapy; Clinical trials; Cyclophosphamide; Diarrhea; Doxorubicin; Epidermal growth factor; ErbB-2 protein; Immunotherapy; Mevalonate pathway; Mevalonic acid; Monoclonal antibodies; Neutropenia; Original Research; Patients; Safety; Surgery; Targeted cancer therapy; Trastuzumab; Tumors; Zoledronic acid; trastuzumab; HER2-positive/HR-positive breast cancer; pathological complete response; neoadjuvant therapy; zoledronic acid
• ISSN: 1758-8359; 1758-8340; 1758-8359
• DOI: 10.1177/1758835919853971

Background: Preclinical evidence suggests that zoledronic acid (ZOL) works synergistically with chemotherapy by enhancing anti-tumor activity. ZOL blocks the mevalonate pathway and may indirectly interact with human epidermal growth factor receptor 2 (HER2) pathway activation. The clinical efficacy and biological rationale of chemotherapy plus anti-HER2 therapy and ZOL as a part of neoadjuvant therapy has not been previously tested. Patients and methods: We conducted a phase II clinical trial to evaluate the efficacy and safety of ZOL as part of a neoadjuvant treatment in patients with HER2-positive breast cancer (BC). The protocol consisted of four cycles of doxorubicin/cyclophosphamide with ZOL, followed by four cycles of docetaxel with trastuzumab and ZOL prior to surgery. The primary endpoint was the pathologic complete response (pCR) rate. Secondary endpoints were safety and the identification of clinicopathological characteristics associated with pCR. Results: A total of 71 patients with stage IIA to IIIB BC were included, with 60 eligible for the safety assessment and 58 for the efficacy analysis. Overall, the pCR rate was 42%, with higher rates in hormone receptor (HR)-positive tumors (40%), which contrasts with the results of pivotal trials. The most commonly observed grade 3 and 4 events were febrile neutropenia (grade 3, 20%; grade 4, 3%) and diarrhea (grade 3, 12%). Conclusions: The addition of ZOL as a repositioning drug in neoadjuvant treatment was an effective and well-tolerated therapy. This drug combination might overcome endocrine and anti-HER2 resistance. The higher pCR rates in the HR-positive subgroup deserve further translational investigation.